Airna
airna.com
Actively hiring
Oncology Therapeutics
Drug Discovery
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$305M
4 rounds on record
Latest round
$155M
Series B · Jan 2025 · 21 mo ago
Team
11-50
employees, estimated range
Hiring now
1
open roles
Backers
1
Nextech Invest
The money's age
Due for its next round
21 months since the last round · hiring slowed
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 2
New executive AIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company Growth · airna.com
Jan 4, 2025
Raised a round Series B $155M · led by Venrock Healthcare Capital Partners · FinanzNachrichten.de
Aug 5, 2024
Raised a round Venture round $90M · Chemical & Engineering News
Jul 30, 2024
Raised a round Venture round $60M
Sep 19, 2023
Launched AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases · businesswire.com
Sep 20, 2021
Raised a round Venture round $1k · SEC Form D
2021
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jan 2025 | $155M | Venrock Healthcare Capital Partners lead, RTW Investments, Nextech Invest | FinanzNachrichten.de |
| Venture round | Aug 2024 | $90M | — | Chemical & Engineering News |
| Venture round | Jul 2024 | $60M | — | businesswire.com |
| Venture round | Sep 2021 | $1k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | AIRNA Corp | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jin Billy LiExecutive Officer, DirectorSEC Form D
Thorsten StafforstExecutive Officer, DirectorSEC Form D
Paul VogelExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Our Science Platform Pipeline REM-422 About Us Our Story Our People Our Investors Our Partners Join Us News News Presentations Press…
Kriya is building durable medicines designed to replace chronic re-treatment with a single administration—therapeutic medicines that can…
Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target…
Cloverleaf Bio is an early-stage therapeutics company developing a new class of engineered RNA therapeutics for cancer therapy. It hires…
SirnaMed is committed to developing innovative therapies that directly target the cause of cancer development, progression and treatment…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
AIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company Growth
- Mr. Bazemore joins AIRNA with over 30 years of experience leading clinical- and commercial-stage biotechs with a focus on rare diseases CAMBRIDGE, Mass., June 2, 2026 - AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives
Read more
Report
AIR-001: A highly potent and precise GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency
The post AIR-001: A highly potent and precise GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency appeared first on Airna.
Read more
Report
RNA Editing: A Modality for Precise Introduction of Gain-of-Function Variants Identified by Human Genetics
The post RNA Editing: A Modality for Precise Introduction of Gain-of-Function Variants Identified by Human Genetics appeared first on Airna.
Read more
Report
AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT
- AIR-001 demonstrated best-in-class potential, achieving up to 59% precise RNA editing in vivo and restoring 40 µM functional M-AAT in a mouse model of AATD - Preclinical data show RNA editing can introduce protective variants for cardiovascular disease
Read more
Report
AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT
Read more
Report
AIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual Meeting
In vivo data support potential best-in-class profile for AIR-001, currently in Phase 1 clinical trial for alpha-1 antitrypsin deficiency (AATD) Data from cardiometabolic portfolio demonstrate promise of AIRNA's approach to introduce beneficial variants CA
Read more
Report
AIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual Meeting
Read more
Report
AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
U.S. Food and Drug Administration grants Orphan Drug Designation to AIR-001 for treatment of AATD Clearance received from regulatory authorities in multiple countries to initiate Phase 1 clinical study Global study will expand to enroll patients at an est
Read more
Report
RNA editing: emerging from CRISPR's shadow
The post RNA editing: emerging from CRISPR's shadow appeared first on Airna.
Read more
Report
RNA editing startup raises $155M to bring liver and lung disease therapy into clinic
The post RNA editing startup raises $155M to bring liver and lung disease therapy into clinic appeared first on Airna.
Read more
Report
Show more news
People
Jin Billy Li
Executive Officer, Director
Thorsten Stafforst
Executive Officer, Director
Paul Vogel
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
44/100
Stable
Open positions
1
0 opened / 0 closed in 30 days
Median time-to-fill
173 days
faster than 7% of the market
ATS activity
Every ~9 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Administrative
100% ▼
Activity Timeline
Added Microsoft Office to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Tübingen
Tübingen
Germany
HQ
1 open roles 10-50 est. staff
hires for Administrative